SubscribeLogin
Published

FDA approves cure for sickle cell disease, the first treatment to use gene-editing tool CRISPR

  • The U.S. FDA has approved Casgevy, the country's first gene-editing treatment, for sickle cell disease patients aged 12 and older.
  • Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR technology to edit genes and treat the disease.
  • Analysts raise concerns about the high cost, complexity, and limited availability of the treatment.
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 63% of the sources are Center
62% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

FDAFDA
North AmericaNorth America
Nobel PrizeNobel Prize
CRISPRCRISPR
HealthHealth
MedicalMedical
United StatesUnited States
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal